Control Systems Engineering for Weight Loss Maintenance
- Disease/Condition
- Overweight and Obesity
- Drug/Device/Intervention
- Intervention Targeting Stress and Emotion Regulation
- Study type
- Interventional
- Intervention type
- behavioral
- Primary sponsor
- The Miriam Hospital
- Location
- Providence, United States of America
- Phase
- Phase 2
- Start date
- Feb 12, 2024
- End date
- Dec 31, 2027
- Enrollment
- 180 participants
Weight change
This project capitalizes on principles of control systems engineering to build a dynamical
 model that predicts weight change during weight loss maintenance using behavioral,
 psychosocial, and environmental indicators evaluated in a system identification experiment. A
 6-month behavioral obesity treatment will be administered to produce weight loss.
 Participants losing at least 3% of initial body weight will be followed for an additional 12
 months via daily smartphone surveys that incorporates passive sensing to objectively monitor
 key behaviors. Survey data pertaining to behavioral, psychosocial, and environmental
 indicators will be used to develop a controller algorithm that can predict when an individual
 is entering a heightened period of risk for regain and why risk is elevated. Interventions
 targeting key risk indicators will be randomly administered during the system ID experiment.
 Survey and passive sensing data documenting the effects of the interventions will likewise
 drive development of the controller algorithm, allowing it to determine which interventions
 are most likely to counter risk of regain.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06244888
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06244888 through Pure Global AI's free database. This Phase 2 trial is sponsored by The Miriam Hospital and is currently Recruiting. The study focuses on Overweight and Obesity. Target enrollment is 180 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.